



15 สิงหาคม 2566

Thai Plaspac

TPAC TB / TPAC.BK

กำไรไตรมาส 2/66 ต่ำกว่าคาด; คาดกำไรเติบโตในไตรมาส 3/66

ต่ำกว่าคาด

TPAC รายงานกำไรสุทธิไตรมาส 2/66 ที่ 114 ล้านบาท เพิ่มขึ้น 151% YoY แต่ลดลง 18% QoQ หากไม่รวมรายการพิเศษ กำไรหลักจะอยู่ที่ 111 ล้าน บาท เพิ่มขึ้น 191% YoY แต่ลดลง 20% QoQ กำไรสุทธิต่ำกว่าที่เราคาด 21% เมืองจากยอดขายต่ำกว่าคาด

ประเด็นสำคัญจากผลประกอบการ

ปัจจัยที่หนุนกำไรหลักให้ขยายตัว YoY ได้แก่ 1) ผลการดำเนินงานของธุรกิจ ในไทยที่ปรับตัวดีขึ้น (อัตรากำไรที่เพิ่มขึ้น), 2) กำไรของธุรกิจต่างประเทศ (อินเดีย, สหรัฐอาหรับเอมิเรตส์, และมาเลเซีย) ที่ เพิ่มขึ้น เนื่องจากการลด ต้นทุนและการเปลี่ยนส่วนผสมผลิตภัณฑ์, และ 3) อัตราภาษีจ่ายที่ลดลง ในขณะที่ปัจจัยกดดันกำไรหลักให้ปรับตัวลดลง QoQ ได้แก่ 1) กำไรของธุรกิจ ต่างประเทศที่ลดลง (โลว์ซีซั่น), 2) ค่าใชจ่ายในการขายและบริหารที่เพิ่มขึ้น โดยอัตราส่วนค่าใช้จ่ายในการขายและบริหารต่อยอดขายเพิ่มขึ้นมาอยู่ที่ 10.7% จาก 9.6% ในไตรมาส 1/66, และ 3) รายได้อื่นๆที่ลดลง

ແບວໂບ້ນ

กำไรหลักไตรมาส 3/66 ของ TPAC มีแนวโน้มเพิ่มขึ้น YoY และ QoQ หนุน โดยอุปสงค์ในวงกว้างที่ปรับตัวดีขึ้นในทุกประเทศที่บริษัทเข้าไปดำเนินการ (อินเดีย ไทย มาเลเซีย และสหรัฐอาหรับเอมิเรตส์) และอัตรากำไรขั้นต้นที่ เพิ่มขึ้น (แรงกดดันด้านต้นทุนที่ลดลง)

สิ่งที่เปลี่ยนแปลง

กำไรสุทธิ 6 เดือนแรกของปี 2566 คิดเป็น 49% ของประมาณการกำไรสุทธิปี 2566 ของเราที่ 522 ล้านบาท ซึ่งเรายังประมาณการกำไรสุทธิดังเดิมไม่ เปลี่ยนแปลง

คำแนะนำ

อุปสงค์บรรจุภัณฑ์ที่เกี่ยวข้องกับสินค้าอุปโภคบริโภคที่เพิ่มขึ้นอย่างรวดเร็ว และการเข้าซื้อกิจการ ส่งผลให้การเติบโตของกำไรในระยะยาวยั่งยืน และอาจ มีอัพไซด์ต่อประมาณการและการประเมินมูลค่าหุ้นของเราจากการลงทุนใหม่ ในอนาคต เรายังคงคำแนะนำ "ซื้อ" Sector: Packaging NEUTRAL

คำแนะนำพื้นฐาน: ซื้อ เป้าหมายพื้นฐาน: 22.00 บาท

เปาหมายพนฐาน: 22.00 บาก ราคา (11/8/66): 18.00 บาท

Key statistics			
Market cap	I	Bt5.9bn	USD0.2bn
12-mth price range	Bt12.5	/Bt18.5	
12-mth avg daily volume		Bt2m	USD0.0m
# of shares (m)		327	
Est. free float (%)		21.0	
Foreign limit (%)		100.0	
Share price perf. (%)	1M	3M	12M
Relative to SET	6.1	14.9	37.7
Absolute	9.1	13.2	32.4

Financial summary										
FY Ended 31 Dec	2022	2023E	2024E	2025E						
Revenues (Btm)	6,997	7,183	7,665	8,108						
Net profit (Btm)	319	522	604	638						
EPS (Bt)	0.98	1.60	1.85	1.95						
EPS grow th (%)	+108.5%	+63.6%	+15.8%	+5.7%						
Core profit (Btm)	297	522	604	638						
Core EPS (Bt)	0.91	1.60	1.85	1.95						
Core EPS growth (%)	+2.7%	+75.7%	+15.8%	+5.7%						
PER (x)	14.3	10.3	8.9	8.4						
PBV (x)	1.8	1.8	1.6	1.4						
Dividend (Bt)	0.3	0.5	0.6	0.6						
Dividend yield (%)	2.1	2.9	3.4	3.6						
ROE (%)	14.7	21.5	21.1	19.3						

CG / CAC Anti-Corruption Certification




สุพพตา ศรีสุข นักวิเคราะห์การลงทุนปัจจัยพื้นฐานด้านหลักทรัพย์ suppata@bualuang.co.th +66 2 618 1343



TPAC: Financial Tables - Year


PROFIT & LOSS (Btm)	2021	2022	2023E	2024E	2025E
Revenue	5,194	6,997	7,183	7,665	8,108
Cost of sales and services	(4,190)	(5,841)	(5,714)	(6,060)	(6,438)
Gross profit	1,004	1,156	1,469	1,606	1,669
SG&A EBIT	(535) 469	(669) 487	(687) 782	(733) 873	(775) 894
Interest expense	(137)	(161)	(158)	(145)	(129)
Other income/exp.	59	77	85	93	103
EBT	390	404	709	821	868
Corporate tax	(78) 312	(75) 328	(132)	(153)	(162) 706
After-tax net profit (loss) Minority interest	(22)	(31)	577 (55)	668 (64)	(68)
Equity earnings from affiliates	0	(31)	0	0	00)
Extra items	(136)	22	0	0	0
Net profit (loss)	153	319	522	604	638
Reported EPS	0.47 0.47	0.98 0.98	1.60 1.60	1.85 1.85	1.95 1.95
Fully diluted EPS Core net profit	289	297	522	604	638
Core EPS	0.89	0.91	1.60	1.85	1.95
EBITDA	955	1,047	1,308	1,439	1,499
KEY RATIOS					
Revenue growth (%)	30.4	34.7	2.7	6.7	5.8
Gross margin (%)	19.3	16.5	20.5	20.9	20.6
EBITDA margin (%)	18.4	15.0	18.2	18.8	18.5
Operating margin (%) Net margin (%)	9.0 2.9	7.0 4.6	10.9 7.3	11.4 7.9	11.0 7.9
Core profit margin (%)	5.6	4.2	7.3	7.9	7.9
ROA (%)	2.6	4.4	6.9	7.8	8.0
ROCE (%)	3.1	5.5	8.8	9.8	10.2
Asset turnover (x)	0.9	1.0	1.0	1.0	1.0
Current ratio (x)	1.3 1.3	1.1 1.3	1.1 1.0	1.1 0.8	1.2 0.6
Gearing ratio (x) Interest coverage (x)	3.4	3.0	5.0	6.0	6.9
BALANCE SHEET (Btm)	0.1	0.0	0.0	0.0	0.0
Cash & Equivalent	394	287	264	250	287
Accounts receivable	1,239	1,373	1,409	1,504	1,591
Inventory	579	536	550	587	621
PP&E-net	2,139	2,342	2,501	2,428	2,326
Other assets Total assets	2,677 7,127	2,701 7,404	2,772 7,667	2,959 7,909	3,129 8,146
Accounts payable	619	602	618	660	698
ST debts & current portion	1,021	1,377	1,403	1,472	1,535
Long-term debt	2,155	1,898	1,664	1,279	894
Other liabilities	725	867	890	950	1,005
Total liabilities Paid-up capital	4,643 327	4,828 327	4,661 327	4,451 327	4,228 327
Share premium	1,027	1,027	1,027	1,027	1,027
Retained earnings	714	947	1,373	1,821	2,278
Shareholders equity	2,133	2,210	2,636	3,084	3,541
Minority interests	350	367	370	374	378
Total Liab.&Shareholders' equity	7,127	7,404	7,667	7,909	8,146
CASH FLOW (Btm)	153	319	522	604	638
Net income Depreciation and amortization	428	482	441	473	503
Change in working capital	(653)	(95)	(86)	(222)	(204)
FX, non-cash adjustment & others	Ó	Ó	Ó	Ó	Ó
Cash flows from operating activities	(72)	706	877	855	937
Capex (Invest)/Divest	(1,091)	(686)	(600)	(400)	(400)
Others Cash flows from investing activities	0 (1,091)	(686)	(600)	(400)	(400)
Debt financing (repayment)	1,149	99	(208)	(316)	(322)
Equity financing	0	0	0	0	0
Dividend payment	(385)	(85)	(96)	(157)	(181)
Others	0	0	0	0	0
Cash flows from financing activities	1,359	(127)	(300)	(469)	(499)
Net change in cash	197	(107)	(23)	(14)	38
Free cash flow (Btm)	(1,162)	21	277	455	537
Key assumptions	2021	2022	2023E	2024E	2025E
Sales volume (kt) Overall utilization rate	63,881 77%	72,465 70%	70,135 72%	75,125 73%	79,592 74%
Overall utilization rate	11/0	1070	12/0	13/0	7 4 70





TPAC: Financial Tables - Quarter

QUARTERLY PROFIT & LOSS (Btm)	2Q22	3Q22	4Q22	1Q23	2Q23
Revenue	1,790	1,834	1,753	1,749	1,644
Cost of sales and services	(1,538)	(1,528)	(1,426)	(1,383)	(1,299)
Gross profit	252	307	327	365	346
SG&A	(183)	(175)	(160)	(168)	(176)
EBIT	69	132	167	197	170
Interest expense	(43)	(43)	(42)	(40)	(41)
Other income/exp.	26	13	16	28	16
EBT	52	102	141	185	145
Corporate tax	(11)	(19)	(28)	(32)	(23)
After-tax net profit (loss)	42	83	112	153	122
Minority interest	(3)	(11)	(10)	(14)	(11)
Equity earnings from affiliates	0	0	0	0	0
Extra items	7	6	4	(0)	4
Net profit (loss)	46	79	106	139	114
Reported EPS	0.14	0.24	0.33	0.43	0.35
Fully diluted EPS	0.14	0.24	0.33	0.43	0.35
Core net profit	38	73	103	139	111
Core EPS	0.12	0.22	0.31	0.43	0.34
EBITDA	194	253	291	314	292
EBITOA				• • • •	
KEY RATIOS					
Gross margin (%)	14.1	16.7	18.6	20.9	21.0
EBITDA margin (%)	10.8	13.8	16.6	18.0	17.8
Operating margin (%)	3.9	7.2	9.5	11.3	10.3
Net margin (%)	2.5	4.3	6.1	7.9	7.0
Core profit margin (%)	2.1	4.0	5.9	8.0	6.7
BV (Bt)	7.9	8.6	7.9	8.1	8.5
ROE (%)	8.3	13.5	18.4	24.6	19.3
ROA (%)	2.4	4.0	5.5	7.6	6.3
Current ratio (x)	1.2	1.2	1.1	1.2	1.1
Gearing ratio (x)	1.4	1.3	1.3	1.2	1.1
Interest coverage (x)	1.6	3.1	4.0	4.9	4.2
QUARTERLY BALANCE SHEET (Btm)					
Cash & Equivalent	195	484	287	206	233
Accounts receivable	1,461	1,498	1,373	1,342	1,347
Inventory	699	580	536	520	525
PP&E-net	2,399	2,502	2,342	2,306	2,422
Other assets	2,872	2,947	2,701	2,645	2,716
Total assets	7,723	8,113	7,404	7,201	7,401
Accounts payable	574	593	602	544	533
ST debts & current portion	1,456	1,590	1,377	1,258	1,407
Long-term debt	2,124	2,107	1,898	1,797	1,717
Other liabilities	908	937	867	861	875
Total liabilities	5,157	5,308	4,828	4,555	4,623
Paid-up capital	327	327	327	327	327
Share premium	1,027	1,027	1,027	1,027	1,027
Retained earnings	750	816	947	1,088	1,106
Shareholders equity	2,211	2,429	2,210	2,305	2,434
Minority interests	355	376	367	342	344
Total Liab.&Shareholders' equity	7,723	8,113	7,404	7,201	7,401



Company profile

Thai Plaspac Plc (TPAC) designs and manufactures rigid plastic packaging for clients in the food & beverage, FMCG, pharmaceutical, personal hygiene, and homecare industries. TPAC's packaging solutions use a selected range of plastic polymers that are all recyclable and/or made from recycled materials. It has a total of 16 production facilities in four countries—India (9), Thailand (4), Malaysia (1), and the United Arab Emirates (2).

Figure 1 : 2Q23 results

FY Ended 31 Dec (Btm)	2Q23	2Q22	YoY %	1Q23	QoQ %	6M23	6M22	YoY %	6M23 vs. FY23E	
Income Statement										
Revenue	1,644	1,790	(8)	1,749	(6)	3,393	3,410	(1)	47	
Cost of sales and services	(1,299)	(1,538)	(16)	(1,383)	(6)	(2,682)	(2,887)	(7)	47	 The revenue contraction was due
EBITDA	292	194	51	314	(7)	607	427	42	46	
SG&A	(176)	(183)	(4)	(168)	5	(344)	(335)	3	50	to lower sales at the overseas
EBIT	170	69	146	197	(14)	367	189	94	47	businesses
Interest expense	(41)	(43)	(4)	(40)	1	(81)	(76)	6	51	5 40.1.0000
Other income/exp.	16	26	(38)	28	(43)	43	48	(9)	51	
Equity earnings from affiliates	0	0	Ö	0	Ö	0	0	0	n.m.	 GM expanded YoY and QoQ
Extra items	4	7	(50)	(0)	nm	4	13	(72)	n.m.	*OW expanded for and gog
EBT	145	52	178	185	(22)	330	161	105	47	
Corporate tax	(23)	(11)	120	(32)	(26)	(55)	(28)	98	42	●Gain on FX
Minority interest	(11)	(3)	218	(14)	(21)	(25)	(11)	122	45	•Gaill Oll I X
Net profit (loss)	114	46	151	139	(18)	253	134	89	49	
Reported EPS	0.35	0.14	151	0.43	(18)	0.78	0.41	89	49	The not profit was below our
Core net profit	111	38	191	139	(20)	250	121	106	48	 The net profit was below our projection
Key ratios										p. 0,000.0
Gross margin (%)	21.0	14.1		20.9		21.0	15.3			
EBITDA margin (%)	17.8	10.8		18.0		17.9	12.5			
EBIT margin (%)	10.3	3.9		11.3		10.8	5.5			
SG&A / Revenue (%)	10.7	10.2		9.6		10.1	9.8			
Tax rate (%)	16.2	20.4		17.2		16.8	17.4			
Net margin (%)	7.0	2.5		7.9		7.5	3.9			
Interest coverage (x)	4.2	1.6		4.9		4.5	2.5			
Balance Sheet										
Cash & Equivalent	233	195	20	206	13					
Total assets	7,401	7,723	(4)	7,201	3					
ST debts & current portion	1,407	1,456	(3)	1,258	12					
Long-term debt	1,717	2,124	(19)	1,797	(4)					
Total liabilities	4,623	5,157	(10)	4,555	1					
Retained earnings	1,106	750	47	1,088	2					
Shareholders equity	2,434	2,211	10	2,305	6					
Minority interests	344	355	(3)	342	1					
BV (Bt)	8.5	7.9	8	8.1	5					

Source: Bualuang Research estimates



Bualuang Securities Public Company Limited

DISCLAIMER

BUALUANG SECURITIES PUBLIC COMPANY LIMITED (BLS) is a subsidiary of BANGKOK BANK PUBLIC COMPANY LIMITED (BBL). This document is produced based upon sources believed to be reliable but their accuracy, completeness or correctness is not guaranteed. The statements or expressions of opinion herein were arrived at after due and careful consideration to use as information for investment. Expressions of opinion contained herein are subject to change without notice. This document is not, and should not be construed as, an offer or the solicitation of an offer to buy or sell any securities. The use of any information shall be at the sole discretion and risk of the user.

BUALUANG SECURITIES PUBLIC COMPANY LIMITED MAY BE IN RELATIONSHIP WITH THE SECURITIES IN THIS REPORT. "Opinions, projections and other information contained in this report are based upon sources believed to be accurate including the draft prospectus, but no responsibility is accepted for any loss occasioned by reliance placed upon the contents hereof. Bualuang Securities Public Company Limited may from time to time perform investment, advisory or other services for companies mentioned in this report, as well as dealing (as principal or otherwise) in, or otherwise being interested in, any securities mentioned herein, This report does not constitute a solicitation to buy or sell any securities". Investors should carefully read details in the prospectus before making investment decision.

BUALUANG SECURITIES PUBLIC COMPANY LIMITED MAY ACT AS MARKET MAKER AND ISSUER OF DWs, AND ISSUER OF STRUCTURED NOTES ON THESE SECURITIES. The company may prepare the research reports on those underlying securities. Investors should carefully read the details of the derivative warrants and structured notes in the prospectus before making investment decisions.

ADVANC	AMATA	AOT	BDMS	BH	CBG	CENTEL	CPALL	GLOBAL	GPSC	IRPC	KBANK	KCE	KTC	MINT
PTG	PTT	PTTEP	PTTGC	SCB	SPRC	TOP	WHA	STA	BGRIM	GULF	MTC	AWC	CRC	CPF
CPN	HANA	HMPRO	IVL	OSP	SAWAD	BANPU	BCH	BTS	SCC	TU	INTUCH	VGI	SCGP	COM7
DOHOME	JMT	CHG	TTB	BAM	BCP	KTB	KKP	OR	BEM	GUNKUL	EA	RBF	STGT	JMART
BEC	KEX	RCL	SINGER	TIDLOR	FORTH	DELTA	SABUY	CKP	TRUE	PSL	SIRI	TQM	CK	ERW
MEGA	SNNP	TLI	STEC	EGCO										

BUALUANG SECURITIES PUBLIC COMPANY LIMITED IS OR MAY BE AN UNDERWRITER/CO-UNDERWRITER/JOINT LEAD IN RESPECT OF THE INITIAL PUBLIC OFFERING (IPO) OF SECURITIES.

Financial Advisor	Lead underwriter/ Underwriter/ Co-underwriter
	KCG, COCOCO

CG Rating

Score Range	Score Range	Description
90 – 100		Excellent
80 – 89		Very Good
70 – 79		Good
60 – 69		Satisfactory
50 – 59		Pass
Below 50	No logo given	N/A

Thailand's Private Sector Collective Action Coalition Against Corruption programme (Thai CAC) under Thai Institute of Directors

- companies that have declared their intention to join CAC, and
- · companies certified by CAC.



CORPORATE GOVERNANCE REPORT DISCLAIMER

This research report was prepared by Bualuang Securities Public Company Limited and refers to research prepared by Morgan Stanley. Morgan Stanley does not warrant or guarantee the accuracy or completeness of its research reports. Morgan Stanley reserves copyright and other proprietary rights in the material reproduced in this report. Morgan Stanley is under no obligation to inform Bualuang Securities or you if the views or information referred to or reproduced in this research report change.

Corporate Governance Report disclaimer

The disclosure of the survey result of the Thai Institute of Directors Association (IOD) regarding corporate governance is made pursuant to the policy of the Office of the Securities and Exchange Commission. The IOD survey is based on the information of a company listed on the Stock Exchange of Thailand and the Market for Alternative Investment disclosed to the public and able to be accessed by a general public investor. The result, therefore, is from the perspective of a third party. It is not an evaluation of operation and is not based on inside information.

The survey result is as of the date appearing in the Corporate Governance Report of Thai Listed Companies. As a result, the survey result may be changed after that date. Bualuang Securities Public Company Limited neither confirms nor certifies the accuracy of such survey results.

"Disclaimer: The disclosure of the Anti-Corruption Progress Indicators of a listed company on the Stock Exchange of Thailand, which is assessed by the relevant institution as disclosed by the Office of the Securities and Exchange Commission, is made in order to comply with the policy and sustainable development plan for the listed companies. The relevant institution made this assessment based on the information received from the listed company, as stipulated in the form for the assessment of Anti-corruption which refers to the Annual Registration Statement (Form 56-1), Annual Report (Form 56-2), or other relevant documents or reports of such listed company. The assessment result is therefore made from the perspective of a third party. It is not an assessment of operation and is not based on any inside information. Since this assessment is only the assessment result as of the date appearing in the assessment result, it may be changed after that date or when there is any change to the relevant information. Nevertheless, Bualuang Securities Public Company Limited neither confirms, verifies, nor certifies the accuracy and completeness of the assessment result."

BUALUANG RESEARCH - RECOMMENDATION FRAMEWORK

STOCK RECOMMENDATIONS

BUY: Expected positive total returns of 15% or more over the next 12 months

HOLD: Expected total returns of between -15% and +15% over the next 12 months.

SELL: Expected negative total returns of 15% or more over the next 12 months.

TRADING BUY: Expected positive total returns of 15% or more over the next 3 months.

SECTOR RECOMMENDATIONS

OVERWEIGHT: The industry, as defined by the analyst's coverage universe, is expected to outperform the relevant primary market index over the next 12 months. **NEUTRAL:** The industry, as defined by the analyst's coverage universe, is expected to perform in line with the relevant primary market index over the next 12 months.

UNDERWEIGHT: The industry, as defined by the analyst's coverage universe, is expected to underperform the relevant primary market index over the next 12 months.



IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report was prepared by Bualuang Securities Public Company Limited ("BLS"). BLS is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act").

Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through BLS. Rosenblatt Securities Inc. accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of Rosenblatt Securities Inc. and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

Additional Disclosures

This research report is for distribution only under such circumstances as may be permitted by applicable law. This research report has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This research report is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report. Neither BLS nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this research report or lack of care in this research report's preparation or publication, or any losses or damages which may arise from the use of this research report.

BLS may rely on information barriers, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of BLS.

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States.

The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by BLS with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior consent of BLS and BLS accepts no liability whatsoever for the actions of third parties in this respect.